59.72
2.29 (3.99%)
| Previous Close | 57.43 |
| Open | 57.34 |
| Volume | 411,729 |
| Avg. Volume (3M) | 408,916 |
| Market Cap | 2,947,683,584 |
| Price / Earnings (TTM) | 746.50 |
| Price / Earnings (Forward) | 140.85 |
| Price / Sales | 12.49 |
| Price / Book | 11.22 |
| 52 Weeks Range | |
| Earnings Date | 26 Feb 2025 - 3 Mar 2025 |
| Profit Margin | 1.56% |
| Operating Margin (TTM) | -4.26% |
| Diluted EPS (TTM) | 0.080 |
| Quarterly Revenue Growth (YOY) | 27.00% |
| Total Debt/Equity (MRQ) | 37.85% |
| Current Ratio (MRQ) | 4.61 |
| Operating Cash Flow (TTM) | 46.01 M |
| Levered Free Cash Flow (TTM) | -12.77 M |
| Return on Assets (TTM) | -0.22% |
| Return on Equity (TTM) | 1.54% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Vericel Corporation | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | -1.5 |
| Price Volatility | -3.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 2.0 |
| Average | -0.30 |
|
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in various therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.92% |
| % Held by Institutions | 104.53% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 67.00 (Canaccord Genuity, 12.19%) | Buy |
| 67.00 (Truist Securities, 12.19%) | Buy | |
| Median | 66.00 (10.52%) | |
| Low | 60.00 (HC Wainwright & Co., 0.47%) | Buy |
| Average | 65.00 (8.84%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 57.73 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 03 Feb 2025 | 67.00 (12.19%) | Buy | 58.54 |
| 19 Nov 2024 | 60.00 (0.47%) | Buy | 55.83 | |
| HC Wainwright & Co. | 15 Jan 2025 | 60.00 (0.47%) | Buy | 57.55 |
| 08 Nov 2024 | 60.00 (0.47%) | Buy | 54.00 | |
| Stephens & Co. | 15 Jan 2025 | 65.00 (8.84%) | Buy | 57.55 |
| Truist Securities | 18 Dec 2024 | 67.00 (12.19%) | Buy | 56.25 |
| BTIG | 26 Nov 2024 | 66.00 (10.52%) | Buy | 58.75 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| SIEGAL JONATHAN | - | 60.11 | -3,908 | -234,910 |
| Aggregate Net Quantity | -3,908 | |||
| Aggregate Net Value ($) | -234,910 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 60.11 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| SIEGAL JONATHAN | Officer | 28 Jan 2025 | Automatic sell (-) | 3,908 | 60.11 | 234,910 |
| SIEGAL JONATHAN | Officer | 28 Jan 2025 | Option execute | 3,908 | - | - |
| Date | Type | Details |
|---|---|---|
| 14 Jan 2025 | Announcement | Vericel Announces Preliminary 2024 Financial Results, 2025 Financial Guidance and Increased Mid-Term Profitability Targets |
| 08 Jan 2025 | Announcement | Vericel to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 |
| 07 Nov 2024 | Announcement | Vericel Reports Third Quarter 2024 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |